Overview

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Status:
Recruiting
Trial end date:
2025-06-01
Target enrollment:
Participant gender:
Summary
This study is being done in order to evaluate the effectiveness of using two drugs (olaparib and ceralasertib) to treat patients with osteosarcoma that has not responded to treatment or has come back after treatment The names of the study drugs involved in this study are: - Olaparib - Ceralasertib
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
AstraZeneca
Osteosarcoma Institute
Treatments:
Olaparib